Hologic (NASDAQ:HOLX) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Hologic, Inc. (NASDAQ:HOLX). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Hologic stock on March 31st. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 4/1/2025.
• Sold $1,001 - $15,000 in shares of W. R. Berkley NYSE: WRB on 4/1/2025.
• Sold $15,001 - $50,000 in shares of GoDaddy NYSE: GDDY on 4/1/2025.
• Purchased $1,001 - $15,000 in shares of Ford Motor NYSE: F on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 3/31/2025.
• Purchased $1,001 - $15,000 in shares of Boeing NYSE: BA on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Viatris NASDAQ: VTRS on 3/31/2025.

Hologic Stock Up 1.2 %

HOLX traded up $0.69 during trading on Friday, hitting $57.85. The stock had a trading volume of 4,235,273 shares, compared to its average volume of 1,911,277. The stock has a 50 day simple moving average of $62.47 and a two-hundred day simple moving average of $71.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a twelve month low of $56.27 and a twelve month high of $84.67. The company has a market capitalization of $12.98 billion, a PE ratio of 18.25, a PEG ratio of 2.14 and a beta of 0.82.

Remove Ads

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on HOLX. Morgan Stanley lowered their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Citigroup dropped their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Evercore ISI reduced their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Raymond James reiterated an "outperform" rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Stephens restated an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $84.62.

Institutional Trading of Hologic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter valued at about $26,000. Groupama Asset Managment grew its holdings in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC increased its position in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.